Search

Displaying results 2121 - 2130 of 10000 in total
  1. Drug

    Resorcinol

    go.drugbank.com/drugs/DB11085
    ApprovedInvestigational

    Resorcinol works by helping to remove hard, scaly, or roughened skin.

    Mixtures: BUCO-BLEU KOLLUTUVAR, 15 ML, DG Health Feminine Anti-itchSynonyms: m-Hydroquinone, m-hydroxyphenol
  2. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. … This makes it useful for some types of pain that don't respond well to other opioids.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  3. Drug

    LAX-101

    go.drugbank.com/drugs/DB05301
    Investigational

    The molecules of EPA found in LAX-101 are identical to the molecules of EPA found in fish oil food supplements. … LAX-101 treats hungtington’s disease, not just the symptoms but the disease itself. The active molecule in LAX-101 is Eicosapentaenoic Acid (EPA). All molecules of EPA are identical.

  4. Drug

    SOT-107

    go.drugbank.com/drugs/DB05337
    Investigational

    SOT-107 is a drug that is a combination of a protein called transferrin and a poison called diphtheria toxin. This drug treat for a type of brain cancer called a high grade glioma brain tumour.

    Synonyms: Transferrin-CRM 107
  5. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … IMM-101 is a heat-inactivated immune-activating mycobacterial product.

  6. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42230] It can recognize and bind two different targets simultaneously, CD20 on cancer B-cells and CD3 on T-cells, allowing it to redirect T-cell cytotoxic activity to cancer cells. … [A249320,A249390] Mosunetuzumab has the potential to circumvent resistance to [rituximab] in patients with follicular lymphoma,[A249320,L42230] and unlike CAR-T therapies such as [axicabtagene ciloleucel

    Products: Lunsumio 1mg/ml Concentrate for Solution for Infusion
  7. Drug

    Ciprocinonide

    go.drugbank.com/drugs/DB18738
    ApprovedWithdrawn

    Synonyms: 6α,9-Difluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-cyclopropanecarboxylate, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone, 21-cyclopropanecarboxylate
  8. Drug

    Lesinidase alfa

    go.drugbank.com/drugs/DB15267
    Investigational

    Lesinidase alfa is under investigation in clinical trial NCT02324049 (Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)).

    Synonyms: SBC-103
  9. Drug

    Dihydroxyaluminum sodium carbonate

    go.drugbank.com/drugs/DB15825
    Investigational

    Products: KOMPENSAN 340 MG TABLET, 60 ADET, KOMPENSAN 340 MG TABLET, 40 ADET
  10. Drug

    KYV-101

    go.drugbank.com/drugs/DB23168
    Investigational

    KYV-101 is under investigation in clinical trial NCT06152172 (CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101).